ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 411

Early Menopause, Smoking and Circulating Antibodies Against Citrullinated Peptides in the Pre-Clinical Phase of Rheumatoid Arthritis

Mitra Pikwer1, Johan Rönnelid2, Monika Hansson3, Ulf Bergström1, Lennart T.H. Jacobsson4, Linda Mathsson2, Per Johan Jakobsson5, Guy B. Serre6, Rikard Holmdahl7, Lars Klareskog8 and Carl Turesson4, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 5Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 6Laboratory of Epidermis differentiation and Rheumatoid autoimmunity, Centre National de la Recherche Scientifique - Université de Toulouse, Toulouse, France, 7Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 8Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), hormones and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Previous studies indicate that anti-citrullinated peptide antibodies (ACPAs) may be detected in individuals who later develop rheumatoid arthritis (RA) years before onset, and that smoking and early menopause (before age 46) are risk factors for RA. Whereas smoking is a predictor of seropositive RA, early menopause has been associated with a milder, predominantly rheumatoid factor negative, phenotype. The objective of this study was to investigate circulating ACPAs and their relation to age at menopause and smoking before the onset of RA.

Methods:

Incident cases of RA were identified among participants (n=30447; 18326 women) in a community based health survey, which was linked to local and national registers, followed by a structured review of the medical records. One control, matched for age, sex and year of inclusion in the health survey, was selected for each validated case. Using a multiplex assay system, sera from 131 female pre-RA cases and 131 controls were investigated for 12 different ACPA fine specificities.  For all investigated antibodies, previous studies had shown good correlations between results obtained using this system and standard ELISAs. Corrected net values for ACPA specificity were calculated by subtracting values for arginine control peptides from the corresponding citrullinated peptides. Cut offs were set at the 98thpercentile, based on investigation of sera from the matched controls. Analyses were stratified by time from inclusion in the health survey to RA diagnosis (1-4, 5-7 and 8-13 years, respectively), and by age at menopause (≤ 45 years vs > 46 years) or history of ever smoking.

Results:

Serum was available from 131 women, who were diagnosed with RA a median of 5.5 years (IQR 3-8; range 1-13) after inclusion in the health survey. Seventy (53 %) of the pre-RA cases were positive for ≥ 1 ACPA. Significantly greater numbers of positive ACPA specificities were detected among pre-RA cases sampled closer to RA diagnosis (p for trend 0.03). A history of early menopause (p=0.001) and ever smoking (p=0.003) were both associated with subsequent development of RA. Ever smokers were more likely to be positive for most ACPAs and had higher numbers of positive ACPA specificities compared to never smokers (p=0.047). Ever smokers were more likely to be positive for ≥ 1 ACPA compared to never smokers, regardless of the time from inclusion to RA diagnosis. By contrast, women with a history of early menopause were less likely to be positive for ≥ 1 ACPA compared to those with normal or late menopause, in particular among cases included ≥ 8 years before RA diagnosis (29 % vs. 48 %).

Conclusion: The early occurrence of ACPA and the increase in ACPA specificities with a shorter time to diagnosis indicate that epitope spreading may precede disease onset. The immune phenotype in the pre-clinical phase of RA may differ between subsets depending on environmental exposures and associated disease mechanisms. The present results suggest that hormonal changes influence pathways in the pathogenesis of RA that are distinct from those associated with smoking.


Disclosure:

M. Pikwer,
None;

J. Rönnelid,
None;

M. Hansson,
None;

U. Bergström,
None;

L. T. H. Jacobsson,
None;

L. Mathsson,
None;

P. J. Jakobsson,
None;

G. B. Serre,
None;

R. Holmdahl,
None;

L. Klareskog,
None;

C. Turesson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-menopause-smoking-and-circulating-antibodies-against-citrullinated-peptides-in-the-pre-clinical-phase-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology